Why is COIN stock down today? Coinbase earnings have investors spooked
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
29 minutes ago
- Yahoo
Befesa S.A. (ETR:BFSA) Just Released Its Half-Year Earnings: Here's What Analysts Think
Befesa S.A. (ETR:BFSA) came out with its half-yearly results last week, and we wanted to see how the business is performing and what industry forecasters think of the company following this report. Revenues came in 2.8% below expectations, at €602m. Statutory earnings per share were relatively better off, with a per-share profit of €1.27 being roughly in line with analyst estimates. Earnings are an important time for investors, as they can track a company's performance, look at what the analysts are forecasting for next year, and see if there's been a change in sentiment towards the company. With this in mind, we've gathered the latest statutory forecasts to see what the analysts are expecting for next year. Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit. After the latest results, the ten analysts covering Befesa are now predicting revenues of €1.28b in 2025. If met, this would reflect a satisfactory 5.1% improvement in revenue compared to the last 12 months. Statutory earnings per share are predicted to ascend 19% to €2.10. Yet prior to the latest earnings, the analysts had been anticipated revenues of €1.32b and earnings per share (EPS) of €2.05 in 2025. If anything, the analysts look to have become slightly more optimistic overall; while they decreased their revenue forecasts, EPS predictions increased and ultimately earnings are more important. Check out our latest analysis for Befesa The consensus has made no major changes to the price target of €35.40, suggesting the forecast improvement in earnings is expected to offset the decline in revenues next year. There's another way to think about price targets though, and that's to look at the range of price targets put forward by analysts, because a wide range of estimates could suggest a diverse view on possible outcomes for the business. The most optimistic Befesa analyst has a price target of €42.00 per share, while the most pessimistic values it at €28.00. This shows there is still a bit of diversity in estimates, but analysts don't appear to be totally split on the stock as though it might be a success or failure situation. One way to get more context on these forecasts is to look at how they compare to both past performance, and how other companies in the same industry are performing. It's pretty clear that there is an expectation that Befesa's revenue growth will slow down substantially, with revenues to the end of 2025 expected to display 11% growth on an annualised basis. This is compared to a historical growth rate of 15% over the past five years. By way of comparison, the other companies in this industry with analyst coverage are forecast to grow their revenue at 4.6% annually. So it's pretty clear that, while Befesa's revenue growth is expected to slow, it's still expected to grow faster than the industry itself. The Bottom Line The most important thing here is that the analysts upgraded their earnings per share estimates, suggesting that there has been a clear increase in optimism towards Befesa following these results. They also downgraded Befesa's revenue estimates, but industry data suggests that it is expected to grow faster than the wider industry. Still, earnings per share are more important to value creation for shareholders. There was no real change to the consensus price target, suggesting that the intrinsic value of the business has not undergone any major changes with the latest estimates. With that in mind, we wouldn't be too quick to come to a conclusion on Befesa. Long-term earnings power is much more important than next year's profits. We have forecasts for Befesa going out to 2027, and you can see them free on our platform here. And what about risks? Every company has them, and we've spotted 2 warning signs for Befesa you should know about. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Higher-tier, extended stay hotels dominate Q2 construction pipeline
This story was originally published on Hotel Dive. To receive daily news and insights, subscribe to our free daily Hotel Dive newsletter. At the midway point of 2025, the total U.S. hotel construction pipeline was up year over year, with upper-tier chain scales and extended stay properties driving growth, according to Lodging Econometrics' Q2 2025 U.S. Hotel Construction Pipeline Trend Report. Standing at 6,280 projects, or 737,036 rooms, the hotel construction pipeline was up 3% year over year in Q2, the report detailed. The pipeline was down sequentially from Q1, though, when it comprised 6,376 projects, or 749,561 rooms. By the numbers 6,280 Number of projects in the total U.S. hotel construction pipeline at the end of Q2 2025 +13% Year-over-year increase in the number of U.S. hotel projects in the early planning stage 199 Number of projects in Dallas' hotel pipeline, the largest of any other U.S. market in Q2 2025 At the close of Q2, there were 1,120 projects under construction and 2,263 projects slated to start construction within the next 12 months, with both categories down slightly year over year, per Lodging Econometrics. Meanwhile, the number of projects in the early planning stage (2,897) was up 13% year over year at the quarter's end. Upper-tier segments, extended stay dominate Upper-tier chain scales dominated the U.S. hotel pipeline in the second quarter, per Lodging Econometrics. Upper midscale had the highest project count (2,282) of all chain scales in its pipeline. The upscale segment had the second largest pipeline in Q2, totaling 1,427 projects, or 177,756 rooms. Together, the upscale and upper midscale segments comprised 59% of all projects in the total pipeline in the quarter, the report detailed. Lodging Econometrics also noted that the upper upscale project pipeline experienced notable growth in Q2, increasing 11% year over year to 360 projects. Upper-tier categories had a leg up over other chain scales in the first quarter this year as well. Meanwhile, extended stay brands continued to remain popular with developers, accounting for 38% of the projects under construction, 43% of those scheduled to begin within the next 12 months and 37% of projects in the early planning stage, according to Lodging Econometrics. The total extended stay pipeline stood at 2,473 projects, representing 39% of the total pipeline and increasing 3% year over year. Earlier this year, Choice Hotels International CEO Patrick Pacious said extended stay and upscale limited service are the two segments with the highest developer and guest demand. Hotel markets to watch Dallas had the largest hotel construction pipeline of any U.S. market at the close of the second quarter, with 199 projects and a record 24,497 rooms, according to Lodging Economics. Dallas' Q2 rooms pipeline was only one room larger than in Q1, though, when it comprised 24,496 rooms. And the city's Q2 project pipeline was slightly down quarter over quarter. Following Dallas for the largest pipelines nationwide were Atlanta with 165 projects; Nashville, Tennessee, with 128 projects; Austin, Texas, with a record 125 projects; and Phoenix with 123 projects. All of these markets showed year-over-year pipeline growth in Q2, though Austin expanded most substantially with a 10% increase in projects. Some 329 new hotels opened in the first half of the year, with Atlanta leading other U.S. markets for the most hotel projects to open (11) during the period, per the report. Dallas saw the second-most hotel projects open (10), followed by New York City (9), Tampa (7) and Orlando, Florida (6). An additional 406 hotels are slated to open across the U.S. by year-end, bringing the total number of hotels opening in 2025 to 735, representing 1.5% year-over-year growth. New York City is forecast to open another 23 new hotels in the second half of the year, the most of any market, per Lodging Econometrics. Notable hotels opening this year in New York City include Waldorf Astoria New York and W New York - Union Square. Looking ahead, Lodging Econometrics projects 823 new U.S. hotels will open nationwide in 2026, increasing 1.6% year over year, and 902 hotels will open in 2027, representing 1.7% annual supply growth that year. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Here's What Key Metrics Tell Us About Moderna (MRNA) Q2 Earnings
For the quarter ended June 2025, Moderna (MRNA) reported revenue of $142 million, down 41.1% over the same period last year. EPS came in at -$2.13, compared to -$3.33 in the year-ago quarter. The reported revenue compares to the Zacks Consensus Estimate of $127.17 million, representing a surprise of +11.66%. The company delivered an EPS surprise of +28.76%, with the consensus EPS estimate being -$2.99. While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance. Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance. Here is how Moderna performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts: Product sales- United States: $88 million versus the three-analyst average estimate of $28.31 million. The reported number represents a year-over-year change of -45.7%. Product sales- Rest of world: $26 million compared to the $42.95 million average estimate based on two analysts. The reported number represents a change of +18.2% year over year. Revenue- Net Product sales: $114 million versus $81.42 million estimated by eight analysts on average. Compared to the year-ago quarter, this number represents a -38% change. Revenue- Other revenue: $28 million versus the six-analyst average estimate of $25.13 million. The reported number represents a year-over-year change of -50.9%. Revenue- Other revenue- Grant revenue: $5 million compared to the $6.16 million average estimate based on three analysts. Revenue- Other revenue- Licensing & royalty revenue: $2 million versus $10.65 million estimated by two analysts on average. Revenue- Other revenue- Collaboration revenue: $4 million versus the two-analyst average estimate of $7.5 million. View all Key Company Metrics for Moderna here>>> Shares of Moderna have returned -3.1% over the past month versus the Zacks S&P 500 composite's +2.3% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Moderna, Inc. (MRNA) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
